Medicare Opens the Door: Part D Begins Covering Zepbound at ~$50 for Qualifying Patients (Mid-2026)

The longest-standing "no" in obesity medicine flipped in mid-2026: Medicare Part D began covering Zepbound for qualifying patients at roughly a $50 monthly copay — the first Medicare coverage of an obesity medication, made possible by the manufacturer pricing agreements struck with the administration in 2025.

The qualifiers matter: coverage is criteria-bound (indication, documentation, and plan mechanics apply), it arrived alongside — not instead of — Wegovy's existing cardiovascular-indication Medicare pathway, and government-program beneficiaries remain excluded from the manufacturers' cash savings offers, making the coverage door and the self-pay door mutually exclusive.

The market math is blunt. For a newly eligible Medicare patient, ~$50/month beats every number on this site — the $215 verified compounded floor, the $299–$449 brand tiers, all of it — by a multiple. Which is why our standing advice got its 2026 update: before shopping the cash market, check every coverage door, in the order laid out in the insurance guide and the insurance-navigator rankings. The cheapest GLP-1 in America is now, for the right patient, a copay.